Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Piribedil in Parkinson's syndrome: a clinical study.

Literature DB >> 183960

Piribedil in Parkinson's syndrome: a clinical study.

Abstract

The effect of a new dopamine receptor stimulating agent, piribedil (ET 495), was studied in 10 patients with Parkinson's syndrome, who had had no or a poor response to previous L-DOPA treatment, or had displayed marked side effects during L-DOPA administration. Piribedil produced significant improvement of the functions of activity of daily living (ADL), and appeared to have a preferential effect on parkinsonian tremor. However, treatment was difficult to control primarily because of severe psychiatric side effects.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1975 PMID： 183960 DOI： 10.1007/bf00567119

Source DB: PubMed Journal: Eur J Clin Pharmacol ISSN： 0031-6970 Impact factor: 2.953

12 in total

Piribedil in Parkinson's syndrome: a clinical study.

1. The occurrence, distribution and physiological role of catecholamines in the nervous system.

2. Apomorphine in Parkinson's disease.

3. Clinical analyses of factors influencing L-dopa treatment of Parkinson's syndrome.

4. Evidence for a new type of dopamine receptor stimulating agent.

5. Evidence for dopamine receptor stimulation by apomorphine.

6. Similarities between neurologic effects of L-dopa and of apomorphine.

7. ET495 and brain catecholamine mechanisms: evidence for stimulation of dopamine receptors.

8. Synthesis and vasodilator activity of new piperazine derivatives.

9. Clinical experimentation with apomorphine in Parkinson's disease.

10. Tremor and involuntary movements in monkeys: effect of L-dopa and of a dopamine receptor stimulating agent.

1. Synthesis, antifungal activity, and QSAR studies of 1,6-dihydropyrimidine derivatives.